MA360i tracks how evidence translates into coverage decisions for ctDNA-MRD in solid-tumor drug development.
Public source
Publisher name
Public post
Pharma is quietly building ctDNA-MRD into its cancer trials. A 2024 FDA guidance is the accelerant, and it may be the fastest route to commercial coverage for MRD. In No…
Company
MA360i
Insights that power market access strategy
- Industry
- Information Services
- Location
- San Carlos, US
- Company size
- 2–10 employees
About MA360i
Market Access 360 Insights (MA360i) is transforming diagnostics commercialization and market access by empowering innovative diagnostic labs to get paid for their breakthroughs with AI tools.
See moreLatest activity
Latest activity from MA360i
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Partners4Access
Partners4Access developed PICO+ to identify and consolidate clinical evidence for PICOs in disease areas with limited HTA precedent and clinical guidelines.
Research & Knowledge
Norstella
Norstella published a new MMIT use case showing how IDN-level barriers held back an oncology brand and how the team cleared them using IDN-formulary insights.
Research & Knowledge
Erasmus Centre for Health Economics Rotterdam (EsCHER)
Erasmus Centre for Health Economics Rotterdam (EsCHER) published a new open-access study examining 350 Dutch pharmaceutical reimbursement indications assessed between 2015 and 2024, finding that cost-effectiveness analysis has a practical role in shaping reimbursement decisions.
Research & Knowledge
ACCESS Forum
ACCESS Forum published Part 1 of Issue 5 covering Foundational Resets, including re-building the floor-and-ceiling corridor, retiring Germany and Japan as stable reference points, and designing Phase II/III protocols with multi-market comparator logic before global protocol lock.
Research & Knowledge
Crystallise Ltd